Mirum Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| (Note 2) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $243,188 | $296,683 |
| Short-term investments | 130,499 | 86,644 |
| Accounts receivable | 156,348 | 123,330 |
| Inventory | 25,486 | 24,887 |
| Prepaid expenses and other current assets | 31,108 | 18,140 |
| Total current assets | 586,629 | 549,684 |
| Restricted cash | 1,735 | 1,482 |
| Long-term investments | 126,768 | 8,105 |
| Property and equipment, net | 3,252 | 1,862 |
| Operating lease right-of-use assets | 11,355 | 8,741 |
| Intangible assets, net | 275,649 | 260,921 |
| Other assets | 21,225 | 12,018 |
| Total assets | $1,026,613 | $842,813 |
| Liabilities and Stockholders’ (Deficit) Equity | ||
| Current liabilities: | ||
| Accounts payable | $13,646 | $9,614 |
| Holdback liabilities, current | 24,800 | — |
| Accrued expenses and other current liabilities | 244,634 | 196,185 |
| Total current liabilities | 283,080 | 205,799 |
| Operating lease liabilities, noncurrent | 9,717 | 7,516 |
| Convertible notes payable, net, noncurrent | 731,250 | 309,797 |
| Holdback liabilities, noncurrent | 44,653 | — |
| Other liabilities | 12,099 | 5,011 |
| Total liabilities | 1,080,799 | 528,123 |
| Commitments and contingencies | ||
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 65,209,474 and 51,896,391 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 7 | 5 |
| Additional paid-in capital | 1,513,555 | 981,878 |
| Accumulated deficit | (1,565,692) | (667,544) |
| Accumulated other comprehensive (loss) income | (2,056) | 351 |
| Total stockholders’ (deficit) equity | (54,186) | 314,690 |
| Total liabilities and stockholders’ (deficit) equity | $1,026,613 | $842,813 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.